LncRNA GASL1 inhibits growth and promotes expression of apoptosis‑associated proteins in prostate carcinoma cells through GLUT‑1

Li,Zhiqin; Liu,Hong; Ju,Wen; Xing,Yifei; Zhang,Xiaoping; Yang,Jun

doi:10.3892/ol.2019.10244

LncRNA GASL1 inhibits growth and promotes expression of apoptosis‑associated proteins in prostate carcinoma cells through GLUT‑1

Authors:
- Zhiqin Li
- Hong Liu
- Wen Ju
- Yifei Xing
- Xiaoping Zhang
- Jun Yang
View Affiliations

Affiliations: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Critical Care Medicine, Institute of Anesthesiology and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: April 12, 2019 https://doi.org/10.3892/ol.2019.10244
Pages: 5327-5334
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Growth‑arrest‑associated long non‑coding (lnc)RNA 1 (GASL1) is as newly identified lncRNA that is associated with liver cancer. The present study aimed to investigate the role of GASL1 in prostate carcinoma (PC). Expression levels of GASL1 in prostate tissues and sera from patients with PC and from healthy subjects were detected by reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic and survival curve analyses were performed to evaluate the diagnostic and prognostic values of GASL1 for patients with PC. A GASL1 expression vector was transfected into PC cells prior to assessment of cell proliferation and expression of B cell lymphoma 2 (Bcl‑2) and glucose transporter 1 (GLUT‑1) by Cell Counting Kit‑8 and western blotting, respectively. The results demonstrated that GASL1 was significantly downregulated in the tissue and serum of patients with PC compared to those of healthy subjects. In addition, GASL1 was used to distinguish patients with PC from healthy controls, and low expression levels of GASL1 were associated with short survival time. Expression levels of GASL1 were significantly associated with tumor size. GASL1 overexpression inhibited PC cell growth. Overexpression of GASL1 upregulated Bcl‑2 expression and downregulated GLUT‑1 expression. In conclusion, these data suggested that lncRNA GASL1 may inhibit PC cell proliferation by targeting GLUT‑1.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Lepor H: Surgical treatment of prostate carcinoma. J Urol 197 (2S). S41–S42. 2017.
3	Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, et al: The evolutionary history of lethal metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
4	Yan W, Li H, Zhou Y, Huang Z, Rong S, Xia M, Ji Z, Chen J and Jiang Y: Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy. Urol Oncol. 27:520–524. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lian J, Wu X, He F, Karnak D, Tang W, Meng Y, Xiang D, Ji M, Lawrence TS and Xu L: A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ. 18:60–71. 2011. View Article : Google Scholar : PubMed/NCBI
6	Effert P, Beniers AJ, Tamimi Y, Handt S and Jakse G: Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 24:3057–3063. 2004.PubMed/NCBI
7	Gutschner T and Diederichs S: The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
8	Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Huge A, et al: Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol. 9:1294–1304. 2014. View Article : Google Scholar : PubMed/NCBI
9	Liu X and Gan B: lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1. Cell Cycle. 15:3471–3481. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gasri-Plotnitsky L, Ovadia A, Shamalov K, Nizri-Megnaji T, Meir S, Zurer I, Cohen CJ and Ginsberg D: A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity. Oncotarget. 8:23775–23786. 2017. View Article : Google Scholar : PubMed/NCBI
11	Malik SS, Kazmi Z, Fatima I, Shabbir R, Perveen S and Masood N: Genetic polymorphism of GSTM1 and GSTT1 and risk of prostatic carcinoma-a meta-analysis of 7,281 prostate cancer cases and 9,082 healthy controls. Asian Pac J Cancer Prev. 17:2629–2635. 2016.PubMed/NCBI
12	Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB and Xu J: Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis. 32:1655–1659. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhou W, Wang Z, Tao Z, Ji L, Zhou B, Shen M and Tu H: Differential expression of long non-coding RNAs in prostatic carcinoma cell line LNCaP after occurrence of androgen independent transformation. Int J Clin Exp Pathol. 10:6665–6673. 2017.
14	Hori SS and Gambhir SS: Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med. 3:109ra1162011. View Article : Google Scholar : PubMed/NCBI
15	Grammatikakis I, Panda AC, Abdelmohsen K and Gorospe M: Long noncoding RNAs(lncRNAs) and the molecular hallmarks of aging. Aging (Albany NY). 6:992–1009. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mayfield RD: Emerging roles for ncRNAs in alcohol use disorders. Alcohol. 60:31–39. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang J, Qiu M, Xu Y, Li M, Dong G, Mao Q, Yin R and Xu L: Long noncoding RNA CCAT2 correlates with smoking in esophageal squamous cell carcinoma. Tumour Biol. 36:5523–5528. 2015. View Article : Google Scholar : PubMed/NCBI
18	Li H, Li X, Bai M, Suo Y, Zhang G and Cao X: Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2. Int J Clin Exp Pathol. 8:14793–14799. 2015.PubMed/NCBI
19	Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, et al: Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 25:1432–1439. 2018. View Article : Google Scholar : PubMed/NCBI